Australië - Engels - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tranexamic acid, quantity: 1000 mg - injection, solution - excipient ingredients: water for injections - adults for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. paediatrics for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tranexamic acid -

Australië - Engels - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - tranexamic acid, quantity: 100 mg/ml - injection, solution - excipient ingredients: water for injections - adults,for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics,for the reduction of peri? and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Verenigde Staten - Engels - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 650 mg - lysteda® (tranexamic acid, usp) tablets is indicated for the treatment of cyclic heavy menstrual bleeding [see clinical studies (14) ]. prior to prescribing lysteda, exclude endometrial pathology that can be associated with heavy menstrual bleeding. do not prescribe lysteda to women who are - using combination hormonal contraception - known to have any of the following conditions: active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) a history of thrombosis or thromboembolism, including retinal vein or artery occlusion an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy) - active thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, or cerebral thrombosis) - a history of thrombosis or thromboembolism, including retinal vein or artery occlusion - an intrinsic risk of thrombosis or thromboembolism (e.g., thrombogenic val

Australië - Engels - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - tranexamic acid, quantity: 500 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - intravenous administration,adults,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty.,paediatrics,for the reduction of peri- and post-operative blood loss and the need for blood transfusion in patients undergoing cardiac surgery.

Ierland - Engels - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - soya bean oil, refined; medium chain triglycerides; refined soyabean oil; fish oil, rich in omega-3 acids; l-alanine; l-arginine; glycine (aminoacetic acid); l-histidine; l-isoleucine; l-leucine; l-lysine; l-methionine; l-phenylalanine; l-proline; l-serine; taurine; l-threonine; l-tryptophan; l-tyrosine; l-valine; calcium chloride; sodium glycerophosphate; magnesium sulfate; potassium chloride; sodium acetate; zinc sulfate; glucose - emulsion for infusion - 0 gram(s) - solutions for parenteral nutrition; combinations

Australië - Engels - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - leucine, quantity: 7.3 g/l; phenylalanine, quantity: 5.6 g/l; methionine, quantity: 4 g/l; lysine hydrochloride, quantity: 7.24 g/l (equivalent: lysine, qty 5.8 g/l); isoleucine, quantity: 6 g/l; valine, quantity: 5.8 g/l; histidine, quantity: 4.8 g/l; threonine, quantity: 4.2 g/l; tryptophan, quantity: 1.8 g/l; alanine, quantity: 20.7 g/l; glycine, quantity: 10.3 g/l; arginine, quantity: 11.5 g/l; proline, quantity: 6.8 g/l; tyrosine, quantity: 400 mg/l; serine, quantity: 5 g/l; sodium acetate, quantity: 6 - injection, intravenous infusion - excipient ingredients: sodium metabisulfite; acetic acid; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)